Full Press Release Details
bioAffinity Technologies Presents Results from Flow
Cytometry Analysis of the Lung at CHEST Conference
Powerful platform reveals the lung environment
for diagnosing lung diseases
SAN ANTONIO, TX - Oct. 12, 2022 - bioAffinity
Technologies, Inc., (NASDAQ: BIAF; BIAFW) will present results of its research into the use of flow cytometry for analyzing the lung environment
to detect diseases of the lung at the American College of Chest Physicians (CHEST) 2022 conference Oct. 16-19, 2022.
The presentation, Sputum Analysis By Flow Cytometry
To Assess Lung Health, will be part of the Lung Cancer Assessment and Risk Calculations session on Oct. 19 beginning at 11:15 a.m.
(ET). bioAffinity Research Scientist Lydia Bederka, PhD, will present data showing how flow cytometry can identify reproducible cell populations
from whole sputum samples that can be used in the development of diagnostics for COPD and asthma, and has been used to develop bioAffinity's
initial product, CyPath Lung, that detects early-stage lung cancer.
CyPath Lung is a non-invasive test
that has shown 92% sensitivity and 87% specificity in detecting early-stage lung cancer in individuals at high risk for the disease who
have lung nodules less than 20mm. The test is marketed by Precision Pathology Services in San Antonio, Texas.
"Flow cytometry can provide the foundation for
impactful lung diagnostic tests," said bioAffinity's Chief Science and Medical Officer Vivienne Rebel, MD, PhD. "With
recent improvements in antibody panels, fluorochromes and methods of detecting fluorescent signals, flow cytometry allows for rapid analysis
of large numbers of sputum-derived cells. Automation of flow analysis, which we have achieved with our test for lung cancer, alleviates
the potential bias problem. A flow cytometry platform can therefore provide insights into lung health, similar to the way flow cytometry
gives insights into hematopoietic health and diseases by analyzing blood and bone marrow."
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW)
addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company's
first product, CyPath Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of
early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services.
OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro
to kill cancer cells without harm to normal cells. Research and optimization of the Company's platform technologies are conducted
in its laboratories at The University of Texas at San Antonio.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from the Company's offering of common shares. Forward-looking statements
can be identified by words such as "believes," "expects," "estimates," "intends," "may,"
"plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers
of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any
obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable
Maria Zannes, President & Chief Executive Officer
Investor Relations Contact:
Tiberend Strategic Advisors, Inc.